<DOC>
	<DOCNO>NCT02237170</DOCNO>
	<brief_summary>The purpose protocol perform comprehensive immune monitoring study patient castration-resistant prostate cancer receive Sipuleucel-T effort well understand mechanism action treatment .</brief_summary>
	<brief_title>Immune Monitoring Sipuleucel-T</brief_title>
	<detailed_description>The primary objective study : 1 . Establish phenotype frequency circulate immune cell compartment patient undergoing treatment Sipuleucel-T. 2 . Determine induction quality prostate antigen-specific T cell immunity patient undergoing treatment Sipuleucel-T. 3 . Correlate whole-blood RNA transcript-based signature clinical outcome patient treat Sipuleucel-T. 4 . Evaluate cytokine chemokine milieu peripheral blood pre- post-treatment Sipuleucel-T .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Age &gt; 18 year age Written inform consent obtain Patients castrationresistant prostate cancer initiate SipuleucelT standard therapy No prior systemic chemotherapy metastatic prostate cancer Hemoglobin &gt; 9 mg/dl Patients unable understand research protocol and/or provide inform consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Sipuleucel-T</keyword>
	<keyword>Castration Resistant Prostate Cancer</keyword>
	<keyword>Provenge</keyword>
</DOC>